利用药物遗传结果优化临终关怀中的药物管理:试点研究
Erika N Dreikorn1, Carolyn Maxwell2,3, Kayla Rowe4
1Clinical Translational Science Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Journal of personalized medicine
|November 26, 2025
概括
药物遗传学 (PGx) 测试可以指导宿舍护理中的药物调整,改善复杂需求患者的症状管理. 这项试点研究表明,PGx指导的处方可以提高生命终端的舒适性.
科学领域:
- 药物遗传学 药物遗传学
- 临终关怀医院的护理
- 生命末期症状管理 生命末期症状管理
背景情况:
- 药物遗传学 (PGx) 检查了遗传变异对药物代谢和反应的影响.
- 临终关怀患者经常有多种药物,复杂的症状和有限的预期寿命.
- 在终身护理中,PGx有望优化药物治疗.
研究的目的:
- 评估药物遗传学结果的有用性,以指导药物调整.
- 改善生命末期患者的症状管理.
- 评估PGx指导处方在精准临终关怀计划中的影响.
主要方法:
- 精准临床医疗计划中的十名患者的回顾性图表审查与PGx结果.
- 由PGx培训的药剂师对临床药物遗传学实施联盟 (CPIC) 基于指导方针的建议进行审查.
- 在跨学科宿舍团队会议上讨论PGx发现.
主要成果:
- 患者的平均年龄为85.7岁,平均服用了17.9种药物.
- 在27个审查的处方中确定了可操作的基因药物相互作用,主要用于抗抑郁药和止痛药.
- 根据PGx指导,在改变药物后,三名患者经历了改善的症状控制.
结论:
- 根据PGx指导的处方可以支持宿舍护理中的个性化药物决定.
- 这种方法可以提高生命终端护理中的情感和身体舒适度.
- 虽然PGx尚未被常规应用,但它显示出在临终关怀机构的潜力.
相关概念视频
Drug Dosing: Geriatric Patients
214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
212
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
212
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
186
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
186
Analysis of Population Pharmacokinetic Data
659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Dosage Regimen: Individualization
156
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
156

